Evidence map›Paper›PMID 36478913›Full record

ArticleOncology letters2023

Clinical characteristics of second primary malignancies among first primary malignancy survivors: A single-center study, 2005-2020.

Fenghao Geng, Minghua Liu, Jianhui Chen, Yanli Ge, Shuxia Wei, Fengyu Li, Chunsong Yang, Jianwei Sun, Lijing Gou, Jianyu Zhang and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Fenghao GengLaboratory of Radiation Medicine, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Minghua LiuDepartment of Pharmacy, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Jianhui ChenDepartment of Radiation Medicine, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Yanli GeDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Shuxia WeiDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Fengyu LiDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Chunsong YangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Jianwei SunDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Lijing GouDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Jianyu ZhangDepartment of Oncology, The Hospital of 81st Group Army People's Liberation Army, Zhangjiakou, Hebei 075000, P.R. China.
Shaokai TangDepartment of Radiation Medicine, West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Yi WanDepartment of Health Services, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Jingyue YangDepartment of Oncology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Jie ZhangDepartment of Radiation Medicine, Air Force Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Air Force Medical University · CNWest China Medical Center of Sichuan University · CNXijing Hospital · CNSichuan University · CNWest China Second University Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cancer survivor population is growing due to advances in detection and treatment. For improved long-term patient management, it is critical to examine the clinical characteristics and outcomes of second primary malignancies (SPMs). An SPM is defined as a second distinct pathological diagnosis, with the same or different origin as the first primary malignancy (FPM). In the present retrospective study, categorical clinical variables were compared between subgroups and the impact on overall survival was evaluated. A total of 1,188 patients with an FPM were included, of which 102 experienced an SPM (8.59%). When compared with the patients who did not develop an SPM, patients with an SPM were significantly older at first diagnosis, had a higher pathological stage and higher rates of biliary tract disease and thyroid disease. In addition, patients with an SPM were more likely to have received postoperative chemotherapy (28.43 vs. 12.16%, P<0.0001) and to be long-term consumers of cigarettes and alcohol (25.00 vs. 8.95%, P<0.05). In addition, an increase in the number of regimens received but not in the number of courses of chemotherapy was associated with a reduction in the time interval to SPM development. Non-small cell lung cancer (NSCLC) was the most common type of FPM (18.27%). In patients with NSCLC the occurrence of SPMs was relatively low (5.07%) and the SPM-associated mortality rate was 2.30%. Breast cancer was the second common type of FPM (12.09%). Patients with breast cancer had a relatively high likelihood of developing an SPM (9.30%), for which family history of malignancy and postoperative chemotherapy were identified as potential risk factors. Patients with stomach cancer were the most vulnerable to SPM (17.95%) and patients with digestive tract cancer had the longest time interval between the FPM and SPM development. In addition, thyroid adenoma was identified as a potential risk factor for SCLC. The findings of the present study may provide valuable guidance for the short- and long-term monitoring of FPM survivors.

Indexed as

distributionfirst primary malignancyoverall survivalrisk factorsecond primary malignancytime interval

Identifiers

PMID36478913
PMCPMC9713803
OpenAlexW4309832760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.